128 results
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody
8-K
EX-99.1
FGEN
FibroGen Inc
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, a fully human anti-CTGF
8-K
EX-99.1
c683qt4p
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
ke34hms1xdlr8wo
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
8-K
EX-99.1
65c2dgvzz9tt
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
bh4x q2dkjcfgzf
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
8-K
EX-99.1
to4r3se5a54c2h
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
8-K
EX-99.1
jhpyp1yv hxdxvt1s
8 May 23
FibroGen Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
j858 5t0hy3ngusq
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
S-3ASR
pjru9b2eg9rq5883
8 Aug 22
Automatic shelf registration
5:12pm